XE 820
- CAS NO.:71791-90-7
- Empirical Formula: C35H40N4O6
- Molecular Weight: 612.72
- MDL number: MFCD33398845
- SAFETY DATA SHEET (SDS)
- Update Date: 2023-05-15 10:43:57
What is XE 820?
The Uses of XE 820
Nicardipine (N394500) impurity. Nicardipine is a dihydropyridine calcium channel blocker. Antianginal; antihypertensive.
Properties of XE 820
| Boiling point: | 712.4±60.0 °C(Predicted) |
| Density | 1?+-.0.06 g/cm3(Predicted) |
| solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly), Water (Slightly) |
| form | Solid |
| pka | 7.60±0.50(Predicted) |
| color | Pale Yellow to Light Yellow |
| Stability: | Light sensitive |
Safety information for XE 820
Computed Descriptors for XE 820
New Products
Dexamethasone Sodium Phosphate p-Anisaldehyde m-Tolualdehyde 2-Bromobenzaldehyde 4-Fluorobenzaldehyde 1-Propyl-4-piperidone 3-Amino-3-(3-fluorophenyl)propanoic acid Raloxifene EP Impurity D N-Nitroso Nortriptyline Nitroso Irbesartan 2-(p-Tolyl)acetaldehyde Sulfonic acid Impurity 2,2-dibromo-1-cyclopropyl-2-(2-fluorophenyl)ethan-1-one 5-Chloro-2-Methoxy-4-Picoline 2-Amino-6-nitrobenzoic Acid (6-Nitroanthranilic acid) Cis-3,5 Diacetoxy-1-cyclopentene 3-Bromo-2-Methoxy-4-Methylpyridine 2-Amino-5-Chloro-3-Nitro-6-picoline 3-Methoxy-5-methylpyrazin-2-amine Pentachlorobenzonitrile Budesonide Nicotinic acid RAPAMYCIN Alpha CyclodextrinYou may like
-
71791-90-7 Nicardipine bis alog 98%View Details
71791-90-7 -
71791-90-7 98%View Details
71791-90-7 -
12029-98-0 >98%View Details
12029-98-0 -
Hydrocortisone 50-23-7 >98%View Details
50-23-7 -
106-43-4 Parachlorotoluene >99%View Details
106-43-4 -
Pyrrolidin >98%View Details
123-75-1 -
cis-p-Menth-2,8-diene-1-ol 7212-40-0 >98%View Details
7212-40-0 -
Para Chloro toluene (PCT) 106-43-4 >99%View Details
106-43-4
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
